Thoracic Tumours Register (RTT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02941458|
Recruitment Status : Recruiting
First Posted : October 21, 2016
Last Update Posted : November 17, 2021
Observational, multicenter study in patients with lung cancer and other thoracic tumors.
The GECP, in its commitment to improve the treatment and prognosis of patients with lung cancer and other thoracic tumors, has marked the individualization of treatment according to the expression of markers predictive of response to chemotherapeutic agents and molecular inhibitors of cell proliferation as one of its primary objectives. This could significantly improve the prognosis of patients with lung cancer, and will lead to a radical change in routine clinical practice. The aim of the register is to explore all data available of all patients treated because of thoracic tumours.
|Condition or disease|
Observational, multicenter study in patients with lung cancer and other thoracic tumors. In a prospective and retrospective way, information will be obtained from the clinical history of each patient.
In Europe, patients with lung cancer have a poor prognosis, and there has been only limited improvement between 1999 and 2007. Potential advantages of the centralization of care and the discussion of treatment strategies in multidisciplinary teams, as suggested in other studies,13 require further research. However, the priorities should be to prevent lung cancer by implementing anti-smoking policies and controlling asbestos exposure throughout Europe, such as was recommended by the World Health Organization (WHO) in 2008.14 Other priorities are to reduce levels of residential radon in risk areas, and early diagnosis to improve the results of surgery, which is still the main curative treatment.
The variability in the diagnostic process, treatment and advocacy, as well as the anticipated increase in associated mortality in Spain in coming years, has stimulated the creation of an epidemiological, observational, multicenter study of cases of lung cancer and other thoracic tumors diagnosed and treated by medical personnel, including both thoracic surgeons and medical oncologists. Data from this study will be collected retrospectively and prospectively, so as to enable an extensive study of the epidemiological and therapeutic factors related to the disease.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||10000 participants|
|Target Follow-Up Duration:||10 Years|
|Official Title:||Thoracic Tumours Register|
|Actual Study Start Date :||July 21, 2016|
|Estimated Primary Completion Date :||December 30, 2025|
|Estimated Study Completion Date :||December 30, 2030|
Non-small cell lung cancer
patients treated for a non small cell lung cancer
Small cell lung cancer
patients treated for a small cell lung cancer
patients treated for a mesotelioma
patients treated for a timic cancer
patients treated for a carcinoid cancer
- Describe epidemiology characteristics of lung cancer and other thoracic tumors in Spanish people [ Time Frame: up to 10 years ]To know the epidemiology characteristics of lung cancer and other thoracic tumors in Spain, as well as clinical and histological data, diagnosis, treatments received, and prognostic factors
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02941458
|Contact: Eva Pereiraemail@example.com|
|Principal Investigator:||Mariano Provencio, MD||Hospital Puerta del Hierro|